Revenue earned related to substantive milestone payments under collaboration agreements.

No definition available.

Name:	mdvn_CollaborationRevenueRelatedToSubstantiveMilestones
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commercialization cost sharing payments income (expense) under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_CommercializationCostSharingPaymentsIncomeExpense
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development cost sharing payments income (expense) under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_DevelopmentCostSharingPaymentsIncomeExpense
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of net sales of XTANDI in the United States, pursuant to collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfNetSalesUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of all Sublicensing Income, as defined in agreement, payable to licensor.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSublicensingIncome
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Net amount due from collaboration partner.

+ References

No definition available.

+ Details

Name:	mdvn_ReceivableFromCollaborationPartner
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Share percentage of development and commercialization cost under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_InvestmentTypeAxis=mdvn_DevelopmentAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=mdvn_AstellasPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_DevelopmentCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_CommercialCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of sublicensing income	10.00%
Collaboration revenue percentage of U.S. XTANDI net sales	50.00%	50.00%	50.00%
Deferred revenue, Current		$ 2,822,000
Collaboration receivable	$ 391,558,000	184,737,000
Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue, Current	0	2,800,000
Collaboration receivable	391,600,000	184,700,000
Collaborative agreement [Member] \| Development and sales milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone earned	245,000,000	307,000,000	$ 45,000,000
Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost-sharing payments	60,800,000	63,500,000	46,600,000
Commercialization cost-sharing payments	$ 37,500,000	$ 36,100,000	$ 12,000,000
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	50.00%
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	33.33%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	50.00%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs	66.67%